title: Clinical experience with recombinant molecules for allergy vaccination.
abstract: Numerous allergens have been cloned and produced by the use of recombinant DNA technology. In several cases recombinant variants with reduced IgE-reactivity have also been developed as candidates for allergen specific immunotherapy. Only very few of these proteins have as yet been tested in the clinic, and the major focus has been on birch and grass pollen, two of the most common causes of IgE-mediated allergic disease. This article serves to justify the rational for using recombinant products and reviews the progress that has been made to date with their clinical assessment.
authors.affiliation: Allergopharma Joachim Ganzer KG, Hermann-Koerner-Strasse 52, 21465 Reinbek, Germany. oliver.cromwell@allergopharma.de
authors.forename: Oliver
authors.initials: O
authors.lastname: Cromwell
authors.forename: Verena
authors.initials: V
authors.lastname: Niederberger
authors.forename: Friedrich
authors.initials: F
authors.lastname: Horak
authors.forename: Helmut
authors.initials: H
authors.lastname: Fiebig
mesh_terms: D000485:Allergens / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D000818:Animals; D052179:Antigens, Plant / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D002415:Cats; D003888:Desensitization, Immunologic / Q000379:methods*; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology* / Q000628:therapy*; D007108:Immune Tolerance; D007073:Immunoglobulin E / Q000276:immunology; D011058:Pollen / Q000276:immunology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology / Q000628:therapy
chemical_list: D000485:Allergens; D052179:Antigens, Plant; D011994:Recombinant Proteins; D007073:Immunoglobulin E